MedTrace Logo

Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat

NCT01612260 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2013-01-08

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of Chinese medicine Shensong Yangxin capsule for the chronic cardiac dysfunction complicated with ventricular premature beats.

Conditions

Interventions

DRUG

Shensong Yangxin capsule

ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks

DRUG

placebo Capsule

4 granules t.i.d. po for 12 weeks

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Nanjing Medical University

    collaborator OTHER

  • Third Military Medical University

    collaborator OTHER

  • Cong-xin Huang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-08-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612260 on ClinicalTrials.gov